Climb Bio (CLYM) vs Electra Therapeutics (ETRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Climb Bio is the larger company by market cap ($623.8 million vs $573.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | ETRA |
|---|---|---|
| Share price | $10.86 | $9.14 |
| Market cap | $623.76M | $573.69M |
| 1-day change | +1.40% | -0.22% |
| YTD return | +167.75% | — |
| 1-year return | +549.09% | — |
| 5-year return | -33.64% | — |
| EPS (TTM) | $-0.82 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $15.50 |
| 52-week low | $1.64 | $8.63 |
| Distance from 52-week high | -40.75% | -41.03% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +153.87% | — |
| Average volume | 1.38M | 948.89K |
| Shares outstanding | 57.44M | 62.77M |
| Employees | 28 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CLYM vs ETRA FAQ
Which is bigger, Climb Bio or Electra Therapeutics?
Climb Bio (CLYM) is larger, with a market capitalization of $623.76M compared with $573.69M for Electra Therapeutics (ETRA).
Are Climb Bio and Electra Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Climb Bio and Biotechnology: Biological Products (No Diagnostic Substances) for Electra Therapeutics.